Agilent, Quest team to extend access to Resolution ctDx FIRST NGS test

Agilent Technologies (A) announced an agreement with Quest Diagnostics (DGX). The alliance will enable providers and patients throughout the United States to access the Agilent Resolution ctDx FIRST liquid biopsy next-generation sequencing, NGS, test. Healthcare providers can order the test beginning today. The agreement between Quest and Agilent will enable broad adoption for ctDx FIRST, a single-site premarket approved or ssPMA test performed at the Resolution Bioscience CLIA laboratory in Kirkland, Washington. ctDx FIRST is the first liquid biopsy test approved by the U.S. Food and Drug Administration as a companion diagnostic CDx to identify advanced non-small cell lung cancer NSCLC patients who may benefit from treatment with KRAZATI(TM). KRAZATI ,adagrasib, received accelerated approval as a targeted treatment option for adult patients with KRASG12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC), as determined by an FDA-approved test, who have received at least one prior systemic therapy. ctDx FIRST is also FDA-approved for tumor profiling of the epidermal growth factor receptor,EGFR, gene in accordance with professional guidelines in oncology for patients with advanced non-small cell lung cancer NSCLC . As a professional service, the ctDx FIRST test report includes comprehensive genomic profiling on 109 genes across four types of alterations: single nucleotide variants, indels, copy number amplifications, and fusions.